Mouse Von Hippel-Lindau Protein Monoclonal Antibody | anti-VHL antibody
Mouse Anti Human Von Hippel-Lindau Protein
Applications
ELISA, Western Blot
Purity
VHL antibody was purified from mouse ascitic fluids by protein-G affinity chromatography.
Synonyms
Von Hippel-Lindau Protein; Monoclonal Antibody; Mouse Anti Human Von Hippel-Lindau Protein; Von Hippel-Lindau disease tumor suppressor; pVHL; Protein G7; VHL; RCA1; VHL1; HRCA1; anti-VHL antibody
Host
Mouse
Clonality
Monoclonal
Isotype
Mouse IgG2b heavy chain and kappa light chain.
Clone Number
P52A11AT
Purity/Purification
VHL antibody was purified from mouse ascitic fluids by protein-G affinity chromatography.
Form/Format
1mg/ml containing PBS, pH-7.4, & 0.1% Sodium Azide.
Sterile filtered colorless solution.
Sterile filtered colorless solution.
Applicable Applications for anti-VHL antibody
ELISA (EIA), Western Blot (WB)
Application Notes
VHL antibody has been tested by ELISA and Western blot analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results. Recommended dilution range for Western blot analysis is 1:500 ~ 1,000. Recommended starting dilution is 1:500.
Type
Mouse Anti Human Monoclonal.
Immunogen
Anti-human VHL mAb is derived from hybridization of mouse SP2/O myeloma cells with spleen cells from BALB/c mice immunized with recombinant human VHL amino acids 1-154 purified from E Coli.
Preparation and Storage
For periods up to 1 month store at 4 degree C, for longer periods of time, store at -20 degree C. Prevent freeze thaw cycles.
12 months at -20 degree C. 1 month at 4 degree C.
12 months at -20 degree C. 1 month at 4 degree C.
Related Product Information for anti-VHL antibody
Introduction: Von Hippel-Lindau disease is a dominant inherited syndrome characterized by the predisposition to develop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas and hemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in the VHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-type allele. VHL has two domains: a roughly 100-residue NH2-terminal domain rich in ï sheet (ï-domain) and a smaller ï¡-helical domain (ï¡-domain), held together by two linkers and a polar interface. VHL protein is also involved in the degradation of hypoxia-inducible factor (HIF).
Product Categories/Family for anti-VHL antibody
